Hi guys, Welcome to the Advanced Video Search Engine, and you are watching 5-year update of BFORE: bosutinib vs imatinib in CML. That video is uploaded by VJHemOnc – Video Journal of Hematology & HemOnc at 2023-01-03T08:04:55-08:00. We are promoting this video only for entertainment and educational purpose only. So, I hope you like & enjoy it. [lw2kK3LYhvE]
| Name | 5-year update of BFORE: bosutinib vs imatinib in CML |
| Video Uploader | Video From VJHemOnc – Video Journal of Hematology & HemOnc |
| Upload Date | This Video Uploaded At 03-01-2023 16:04:55 |
| Video Discription | Jorge Cortes, MD, Augusta University, Augusta, GA, summarizes the design and updated findings of the BFORE trial (NCT02130557), which compared the efficacy and toxicity profiles of bosutinib and imatinib in patients with newly diagnosed chronic myeloid leukemia (CML). This study confirmed that bosutinib can be a high-efficacy frontline treatment for patients with CML with a safety profile similar to that of imatinib. This interview took place at the 64th ASH Annual Meeting and Exposition congress in New Orleans, LA. These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved. lw2kK3LYhvE |
| Category | Education |
| Tags | Speaker: Jorge Cortes | Institution: Augusta University | Event: ASH 2022 | Format: Interview | Subject: Chronic Myeloid Leukemia | Subject: Leukemia | Field: Trial Updates | Field: Treatment | Field: Immuno-Oncology | Trial: BFORE | Medicines: Bosutinib | Medicines: Imatinib | immunotherapy | TKI | diarrhea | MR4.5 | toxicity | efficacy | NCT02130557 |
